Breast cancer: Oral SERDs in ER+ BC. Part 1 - Efficacy, safety and the treatment landscape

In this podcast, the experts give an overview of  the EMERALD trial  and present elacestrant as the first, and currently only, oral SERD to be FDA approved. They focus on the efficacy results and landmark analysis not only according to the duration of CDK4/6i prior treatment but also to the presence/absence of ESR1 mutation. Experts also provide a brief discussion on EMERALD trial safety results. The discussion ends with a look at the current treatment landscapeand future perspective for oral SERDs in ER+/HER2- advanced or metastatic breast cancer. Dr.Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr.Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai explore new endocrine therapies for ER+/HER2- advanced or metastatic breast cancer. More specifically, they discuss  oral SERDs efficacy and safety profile as well as their place in treatment landscape 

There are no comments yet.

Please log in to write the first comment.